Literature DB >> 2857753

Immune spleen cell-mediated protection against fatal Hantaan virus infection in infant mice.

T Nakamura, R Yanagihara, C J Gibbs, D C Gajdusek.   

Abstract

To clarify the basis of the age-dependent susceptibility of infant mice to fatal meningoencephalitis caused by Hantaan virus, we investigated the ability of spleen cells from immune and nonimmune weanling BALB/c mice to confer protection to syngeneic infant mice. Intraperitoneal transfer of 10 X 10(7), 5 X 10(7), 2.5 X 10(7), and 1.2 X 10(7) immune spleen cells to infant mice 24 hr after intracerebral challenge with 100 50% lethal doses of Hantaan virus (strain 76-118) resulted in 100%, 70%, 64%, and 30% protection, respectively. Even as late as 48 hr after virus challenge, transfer of 10 X 10(7) immune spleen cells conferred complete protection. In contrast, nonimmune spleen cells offered no protection, even when cells were transferred 48 hr before virus challenge. The protective capacity of immune spleen cells was abolished following treatment with antibody to theta antigen and guinea pig complement, but was preserved after the depletion of B cells, a result suggesting that T cells play a crucial role in the resistance of mice to fatal Hantaan virus infection.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2857753     DOI: 10.1093/infdis/151.4.691

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  16 in total

1.  Role of maternal antibody in protection from hemorrhagic fever with renal syndrome virus infection in rats.

Authors:  X K Zhang; I Takashima; N Hashimoto
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

2.  Role of peripheral blood mononuclear cell (PBMC) phenotype changes in the pathogenesis of haemorrhagic fever with renal syndrome (HFRS).

Authors:  A Markotić; G Dasić; A Gagro; A Sabioncello; S Rabatić; I Kuzman; R Zgorelec; I Smoljan; I Beus; T A Zupanc; D Dekaris
Journal:  Clin Exp Immunol       Date:  1999-02       Impact factor: 4.330

3.  Differential susceptibility and resistance of immunocompetent and immunodeficient mice to fatal Hantaan virus infection.

Authors:  T Nakamura; R Yanagihara; C J Gibbs; H L Amyx; D C Gajdusek
Journal:  Arch Virol       Date:  1985       Impact factor: 2.574

4.  Pathogenicity of Hantaan virus in newborn mice: genetic reassortant study demonstrating that a single amino acid change in glycoprotein G1 is related to virulence.

Authors:  H Ebihara; K Yoshimatsu; M Ogino; K Araki; Y Ami; H Kariwa; I Takashima; D Li; J Arikawa
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

5.  Pathogenesis of experimental Hantaan virus infection in laboratory rats.

Authors:  P W Lee; R Yanagihara; C J Gibbs; D C Gajdusek
Journal:  Arch Virol       Date:  1986       Impact factor: 2.574

6.  Highly differentiated, resting gn-specific memory CD8+ T cells persist years after infection by andes hantavirus.

Authors:  Tobias Manigold; Andrés Mori; Rebecca Graumann; Elena Llop; Valeska Simon; Marcela Ferrés; Francisca Valdivieso; Constanza Castillo; Brian Hjelle; Pablo Vial
Journal:  PLoS Pathog       Date:  2010-02-19       Impact factor: 6.823

7.  Protective role of antigenic sites on the envelope protein of Hantaan virus defined by monoclonal antibodies.

Authors:  J Arikawa; J S Yao; K Yoshimatsu; I Takashima; N Hashimoto
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

8.  Humoral response in Toscana virus acute neurologic disease investigated by viral-protein-specific immunoassays.

Authors:  F Magurano; L Nicoletti
Journal:  Clin Diagn Lab Immunol       Date:  1999-01

9.  Experimental hantavirus infection in nonhuman primates.

Authors:  R Yanagihara; H L Amyx; P W Lee; D M Asher; C J Gibbs; D C Gajdusek
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

10.  Protective immunity of Hantaan virus nucleocapsid and envelope protein studied using baculovirus-expressed proteins.

Authors:  K Yoshimatsu; Y C Yoo; R Yoshida; C Ishihara; I Azuma; J Arikawa
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.